Shares of Steelcase Inc. SCS rose 0.83 percent on Wednesday trading, ahead of the announcement of the company’s second quarter (fiscal 2016) financial results, scheduled for after the bell.
After the small-cap industrials provider reported earnings of $0.35 per share on revenue of $819 million, beating guidance and the Street’s consensus estimate of $0.33 per share and $794.5 million, the shares continued to surge, roughly 3.6 percent, in after-hours trading.
Also surging slightly on its earnings report is Worthington Industries, Inc. WOR. The stock fell 2.58 percent during the regular session, but rose about 0.5 percent in Wednesday’s after-hours, probably driven by the announcement of a quarterly dividend of $0.19 per share. The financial results are yet to be released.
The biggest winner since the bell rang was Conatus Pharmaceuticals Inc CNAT, which continued to surge -about 35 percent- on Wednesday’s after-hours. The stock has been on the rise for almost a month now, but saw the largest gains in the past couple of sessions.
Wednesday’s surge after the market closed was driven by the company’s announcement of possitive top-line results from its “exploratory Phase 2 Portal Hypertension (PH) clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor.” See Press Release for further details.
Baytex Energy Corp (USA) BTE, for its part, seems to be recuperating the ground lost during the day (12.79 percent) in after-hours trading. Since the bell rang, the stock regained 14 percent, and is trading above Wednesday’s opening price of $3.84.
On the other hand, a few stocks falling in Wednesday’s after-hours trading session include:
RealNetworks Inc RNWK, down about 7 percent
Cliffs Natural Resources, Inc. CLV, also down roughly 7 percent
Repligen Corporation RGEN, down more than 6.5 percent
Extreme Networks, Inc EXTR, down almost 6 percent
ChemoCentryx Inc CCXI, down almost 5 percent
Gigamon Inc GIMO, down more than 4.6 percent
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.